ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 14 (2) 221-232    DOI: 10.1677/ERC-06-0074
Copyright © 2007 by the Society for Endocrinology.
This Article
Right arrow Free Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vilar, E.
Right arrow Articles by Tabernero, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vilar, E.
Right arrow Articles by Tabernero, J.

REVIEW

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

Eduardo Vilar, Ramón Salazar1, Jose Pérez-García, Javier Cortes, Kjell Öberg2 and Josep Tabernero

Department of Medical Oncology, Vall d’Hebron University Hospital, Ps. Vall d’Hebron, 119-129, Barcelona 08035, Spain
1 Department of Medical Oncology, Institut Català d’Oncologia, Barcelona, Spain
2 Department of Endocrine Oncology, University Hospital, 751 85 Uppsala, Sweden

(Requests for offprints should be addressed to E Vilar; Email: evilar{at}vhebron.net)

Neuroendocrine tumors (NETs) of the digestive tract are a heterogeneous group of rare malignancies. Three major subgroups can be defined: pancreatic endocrine tumors, carcinoid tumors, and poorly differentiated gastroenteropancreatic NETs. Classically, digestive NETS have been considered to have an indolent course characterized for prolonged stabilizations or slow progressions, but there are clear differences in terms of aggressiveness, clinical course, and response to treatment among them. Retrospective studies have identified several clinicopathological and immunohistochemical factors as angioinvasion and proliferative index assessed by Ki-67 expression, which predict biological behavior and correlate with survival. Chemotherapy regimens based on the combination of several active drugs such as streptozocin, doxorubicin, 5-fluorouracil, dacarbazine, and temozolomide show low response rates, which sets the need to improve the results of the medical treatment of these malignancies. This review will analyze the role of Ki-67 in digestive NETs under a clinical perspective and will suggest future fields for development of this approach that enable a better patient selection for chemotherapy. Also a comprehensive review of the literature about chemotherapy in NETs is presented.




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
A Advani, S Vaikkakara, M S Gill, C S Arun, S H Pearce, S G Ball, R A James, T W J Lennard, R D Bliss, R Quinton, et al.
Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review
J. Clin. Pathol., August 1, 2008; 61(8): 939 - 944.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al.
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
C. Piani, G. M Franchi, C. Cappelletti, M. Scavini, L. Albarello, A. Zerbi, P. Giorgio Arcidiacono, E. Bosi, and M. F Manzoni
Cytological Ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading
Endocr. Relat. Cancer, March 1, 2008; 15(1): 175 - 181.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society for Endocrinology.